ObvioHealth was asked to conduct an observational study of infant crying and fussing.
Caregivers recorded their infants’ crying/fussing and used the ObvioHealth app to provide feedback on their perception of each event through daily questionnaires and e-diaries. Mandatory training and ongoing communication with subjects minimized user-interface issues and improved data integrity.
Reported crying/fussing frequency and duration was 2-3 times higher than audio-recorded events. Results provided insights into device functionality and human bias.
ObvioHealth was asked to conduct an observational study of infant crying and fussing.
Caregivers recorded their infants’ crying/fussing and used the ObvioHealth app to provide feedback on their perception of each event through daily questionnaires and e-diaries. Mandatory training and ongoing communication with subjects minimized user-interface issues and improved data integrity.
Reported crying/fussing frequency and duration was 2-3 times higher than audio-recorded events. Results provided insights into device functionality and human bias.
ObvioHealth was asked to conduct an observational study of infant crying and fussing.
Caregivers recorded their infants’ crying/fussing and used the ObvioHealth app to provide feedback on their perception of each event through daily questionnaires and e-diaries. Mandatory training and ongoing communication with subjects minimized user-interface issues and improved data integrity.
Reported crying/fussing frequency and duration was 2-3 times higher than audio-recorded events. Results provided insights into device functionality and human bias.
ObvioHealth was asked to conduct an observational study of infant crying and fussing.
Caregivers recorded their infants’ crying/fussing and used the ObvioHealth app to provide feedback on their perception of each event through daily questionnaires and e-diaries. Mandatory training and ongoing communication with subjects minimized user-interface issues and improved data integrity.
Reported crying/fussing frequency and duration was 2-3 times higher than audio-recorded events. Results provided insights into device functionality and human bias.
ObvioHealth was asked to conduct an observational study of infant crying and fussing.
Caregivers recorded their infants’ crying/fussing and used the ObvioHealth app to provide feedback on their perception of each event through daily questionnaires and e-diaries. Mandatory training and ongoing communication with subjects minimized user-interface issues and improved data integrity.
Reported crying/fussing frequency and duration was 2-3 times higher than audio-recorded events. Results provided insights into device functionality and human bias.
ObvioHealth was asked to conduct an observational study of infant crying and fussing.
ObvioHealth was asked to conduct an observational study of infant crying and fussing.
Caregivers recorded their infants’ crying/fussing and used the ObvioHealth app to provide feedback on their perception of each event through daily questionnaires and e-diaries. Mandatory training and ongoing communication with subjects minimized user-interface issues and improved data integrity.
Reported crying/fussing frequency and duration was 2-3 times higher than audio-recorded events. Results provided insights into device functionality and human bias.
ObvioHealth was asked to conduct an observational study of infant crying and fussing.
ObvioHealth was asked to conduct an observational study of infant crying and fussing.
Caregivers recorded their infants’ crying/fussing and used the ObvioHealth app to provide feedback on their perception of each event through daily questionnaires and e-diaries. Mandatory training and ongoing communication with subjects minimized user-interface issues and improved data integrity.
Reported crying/fussing frequency and duration was 2-3 times higher than audio-recorded events. Results provided insights into device functionality and human bias.
ObvioHealth successfully conducted a clinical trial for RedHill Biopharma to test the safety and efficacy of an oral medication for the treatment of COVID-19 symptoms. We designed this decentralized study to be conducted where the majority of patients recover from illness—in their homes. When the trial was launched in 2021, its unique combination of home health visits, electronic patient-reported outcomes (ePRO), and remote monitoring devices was pioneering—COVID-19 studies were typically conducted inside hospitals.
ObvioHealth and Renovia conducted a groundbreaking study on the efficacy of an at-home medical device for the treatment of stress and mixed urinary incontinence. Read more below to understand how we delivered a successful, fully virtual clinical trial in the midst of the pandemic.